JP2022524204A5 - - Google Patents

Info

Publication number
JP2022524204A5
JP2022524204A5 JP2021554758A JP2021554758A JP2022524204A5 JP 2022524204 A5 JP2022524204 A5 JP 2022524204A5 JP 2021554758 A JP2021554758 A JP 2021554758A JP 2021554758 A JP2021554758 A JP 2021554758A JP 2022524204 A5 JP2022524204 A5 JP 2022524204A5
Authority
JP
Japan
Prior art keywords
antibody
composition according
region
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021554758A
Other languages
English (en)
Japanese (ja)
Other versions
JP7687956B2 (ja
JP2022524204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/056757 external-priority patent/WO2020187718A1/en
Publication of JP2022524204A publication Critical patent/JP2022524204A/ja
Publication of JP2022524204A5 publication Critical patent/JP2022524204A5/ja
Priority to JP2025085028A priority Critical patent/JP2025126171A/ja
Application granted granted Critical
Publication of JP7687956B2 publication Critical patent/JP7687956B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021554758A 2019-03-15 2020-03-13 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 Active JP7687956B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025085028A JP2025126171A (ja) 2019-03-15 2025-05-21 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19163036.7 2019-03-15
EP19163036 2019-03-15
PCT/EP2020/056757 WO2020187718A1 (en) 2019-03-15 2020-03-13 Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025085028A Division JP2025126171A (ja) 2019-03-15 2025-05-21 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物

Publications (3)

Publication Number Publication Date
JP2022524204A JP2022524204A (ja) 2022-04-28
JP2022524204A5 true JP2022524204A5 (https=) 2023-03-20
JP7687956B2 JP7687956B2 (ja) 2025-06-03

Family

ID=65817862

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021554758A Active JP7687956B2 (ja) 2019-03-15 2020-03-13 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
JP2025085028A Pending JP2025126171A (ja) 2019-03-15 2025-05-21 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025085028A Pending JP2025126171A (ja) 2019-03-15 2025-05-21 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物

Country Status (12)

Country Link
US (1) US20220144965A1 (https=)
EP (1) EP3938394A1 (https=)
JP (2) JP7687956B2 (https=)
KR (1) KR20220002891A (https=)
CN (1) CN113574071B (https=)
AU (2) AU2020242228B2 (https=)
CA (1) CA3130132A1 (https=)
IL (1) IL286343A (https=)
MX (1) MX2021011181A (https=)
SG (1) SG11202107319PA (https=)
TW (1) TW202102541A (https=)
WO (1) WO2020187718A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) * 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
FR3120866B1 (fr) * 2021-03-19 2025-02-28 Univ Toulouse 3 Paul Sabatier Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
TW202321303A (zh) * 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
CN116183930A (zh) * 2022-12-29 2023-05-30 陕西脉元生物科技有限公司 抗insrr抗体在制备检测和/或诊断神经系统相关疾病的产品中的应用
WO2026080575A1 (en) * 2024-10-08 2026-04-16 Human Immunology Biosciences, Inc. Anti-cd38 antibodies and their uses

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2625681C (en) * 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
HUE027683T2 (en) 2007-10-01 2016-10-28 Codexis Inc Ketoreductase polypeptides for the production of azetidinone
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
SMT202000031T1 (it) * 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
SG186397A1 (en) * 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
DK2621531T3 (en) * 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
MX368288B (es) * 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
EA201792546A1 (ru) * 2015-05-20 2018-04-30 Янссен Байотек, Инк. Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
WO2017149122A1 (en) 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma

Similar Documents

Publication Publication Date Title
JP2022524204A5 (https=)
RU2664462C2 (ru) Комбинированная терапия с помощью антитела к CD19 и аналога пурина
US12194095B2 (en) Combinations and uses thereof
JP2008540447A5 (https=)
JP2013542191A5 (https=)
JP2017507954A5 (https=)
JP2013542194A5 (https=)
RU2625222C2 (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
IL275884B1 (en) Human antibodies to influenza hemagglutinin
JP2024540226A5 (https=)
JP2025502061A5 (https=)
JP2025509567A5 (https=)
RU2021128490A (ru) Aнтитела к CD38 и фармацевтические композиции на их основе для лечения аутоиммунного заболевания, опосредованного аутоантителами
NZ777838A (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
NZ777838B2 (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
RU2023132469A (ru) Aнтитела к CD38 и фармацевтические композиции на их основе для лечения аутоиммунного заболевания, опосредованного аутоантителами
JP2022502380A5 (https=)
RU2008140661A (ru) Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
RU2025129547A (ru) Способы применения мультиспецифических связывающих белков
NZ775885B2 (en) Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
NZ743874B2 (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
NZ775885A (en) Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
NZ729816A (en) Combination therapies with anti-cd38 antibodies
NZ729816B2 (en) Combination therapies with anti-cd38 antibodies
NZ738208A (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors